Cannabis Stocks Drop After Early Surge on Limited US Marijuana Rescheduling Move
Cannabis stocks fell after hype faded: US reform helps medical marijuana only, not full market, so investors took profits.
/ 111 items
#XY Event-Driven Stocks↓
Regeneron Strikes Deal with Trump: Free Gene Therapy for Hearing Loss + Lower Drug Prices for Americans
Regeneron will cut U.S. drug prices, offer free gene therapy for hearing loss, and align costs with other countries under a Trump deal.
Grace Therapeutics Gets FDA Feedback on GTx-104: No New Clinical Trials Needed, Resubmission Planned
FDA flagged fixable issues for GTx-104, not rejection. No new trials needed. IV drug may improve brain bleed ICU treatment.
IKS Health Acquires TruBridge to Boost Rural Healthcare Access
IKS Health is buying TruBridge to improve rural US healthcare using AI. Deal helps 2000 hospitals, closes 2026.
Amneal Acquires Kashiv BioSciences in $1.1B Deal to Ride $300 Billion Biosimilar Wave
Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.
Kyverna’s miv-cel Scores Historic Win in Stiff Person Syndrome – First CAR-T Poised for FDA Approval
Kyverna’s CAR-T drug greatly improved rare SPS: patients walked 46% faster, many stopped meds; FDA filing planned 2026.